Comparing HIV treatments for virologically suppressed men
Part of Immune system & allergy, Infections clinical trials.
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man living with HIV and your viral load has been undetectable for at least 48 weeks.
- You have been taking a specific HIV regimen (darunavir/cobicistat plus tenofovir/emtricitabine) for at least 48 weeks.
- You are 18 years or older.
- Your kidney function (GFR) is at least 60 mL/min.
- You are a beneficiary of the Mexican Social Security Institute (IMSS) and receive care at the Infectious Diseases Hospital of 'La Raza' National Medical Center.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Hear when a new Antiretroviral Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.